Technical Analysis for JNCE - Jounce Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.99 | 5.72% | 0.27 |
JNCE closed up 5.72 percent on Monday, March 30, 2020, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Historical JNCE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 200 DMA Resistance | Bearish | 5.72% | |
| Stochastic Reached Overbought | Strength | 5.72% | |
| Wide Bands | Range Expansion | 5.72% | |
| Overbought Stochastic | Strength | 5.72% | |
| 200 DMA Resistance | Bearish | -0.20% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.20% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/27/2020
- Sector: Healthcare
- Industry: Biotechnology
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Biotechnology Life Sciences Biology Natural Sciences Immunology Immunotherapy Solid Tumors Immune System Monoclonal Antibodies
Biotechnology Life Sciences Biology Natural Sciences Immunology Immunotherapy Solid Tumors Immune System Monoclonal Antibodies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.0 |
| 52 Week Low | 2.79 |
| Average Volume | 402,145 |
| 200-Day Moving Average | 5.03 |
| 50-Day Moving Average | 5.34 |
| 20-Day Moving Average | 4.21 |
| 10-Day Moving Average | 4.28 |
| Average True Range | 0.59 |
| ADX | 26.07 |
| +DI | 20.96 |
| -DI | 19.37 |
| Chandelier Exit (Long, 3 ATRs ) | 3.57 |
| Chandelier Exit (Short, 3 ATRs ) | 4.61 |
| Upper Bollinger Band | 5.53 |
| Lower Bollinger Band | 2.90 |
| Percent B (%b) | 0.79 |
| BandWidth | 62.53 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.40 |
| MACD Histogram | 0.2328 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.63 | ||||
| Resistance 3 (R3) | 5.58 | 5.32 | 5.52 | ||
| Resistance 2 (R2) | 5.32 | 5.16 | 5.34 | 5.49 | |
| Resistance 1 (R1) | 5.16 | 5.06 | 5.24 | 5.20 | 5.45 |
| Pivot Point | 4.89 | 4.89 | 4.94 | 4.92 | 4.89 |
| Support 1 (S1) | 4.73 | 4.73 | 4.81 | 4.78 | 4.53 |
| Support 2 (S2) | 4.47 | 4.63 | 4.49 | 4.49 | |
| Support 3 (S3) | 4.30 | 4.47 | 4.46 | ||
| Support 4 (S4) | 4.35 |
